Navigation Links
Cardium Reports on Third Quarter 2008 Financial Results and Revised Business Strategies for Operating Units
Date:11/10/2008

SAN DIEGO, Nov. 10 /PRNewswire-FirstCall/ -- Cardium Therapeutics (Amex: CXM) today reported financial results and highlights for its third quarter ended September 30, 2008, and outlined revised business strategies for its three operating units: (1) InnerCool Therapies, (2) Tissue Repair Company, and (3) Cardium Biologics.
(Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO)

InnerCool Therapies, Inc.

The Company recently announced 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market InnerCool's new RapidBlue(TM) endovascular temperature modulation system. This new system automatically cools or warms patients, as necessary, to quickly and controllably achieve and then maintain a desired body temperature. The RapidBlue System provides rapid or gradual temperature control for all patient sizes and is powerful enough to quickly cool awake patients and may eliminate the need to use paralytic agents. During the quarter, the Company also announced CE mark approval and Underwriters Laboratories, Inc. (UL) certification for the RapidBlue which will allow InnerCool to begin marketing the RapidBlue System in Europe and many other countries that recognize these certifications.

InnerCool's CoolBlue(TM) surface temperature modulation system, which includes a console and a disposable CoolBlue vest with upper thigh pads, is designed to provide a complementary tool for use in less acute patients or in clinical settings best suited to prolonged temperature management. The nurse-friendly and cost-effective CoolBlue System, launched in the U.S. in fourth quarter 2007, is also now availabl
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Cardium Announces FDA 510(K) Clearance of InnerCools RapidBlue(TM) Endovascular System
2. ITGI Medical Received a CE Mark for its Second Pericardium Covered Stent - AneuGraft(R) - for Tortuous Vessels
3. Cardium Announces InnerCools New RapidBlue(TM) System Obtains CE Mark for Commercial Sale in Europe and UL certification
4. Cardium Announces Follow-On Direct Investment by Institutional Investor
5. Cardium Selected for Inclusion in Russell Microcap Index
6. Cardiums InnerCool Therapies Unit Announces Italian Commercialization Agreement for Portfolio of Temperature Modulation Systems
7. Cardium Launches New AWARE Clinical Study Website
8. Over and Under(R) Pericardium Covered Stent is now in use in England and Proves Great Deliverability
9. Cardium Therapeutics Announces Annual Meeting of Stockholders to be Held June 5, 2008
10. Cardium Reports on First Quarter 2008 Highlights and Financial Results
11. Richard A. Schatz, M.D. Joins Cardiums Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... OXFORD, England , May 22, 2013 ... inhaled, novel drug-only formulation of glycopyrronium bromide designed using ... speciality pharmaceutical company developing a portfolio of inhaled ... 2 clinical study with PSX1002 that will assess its ... range of doses in patients with moderate to severe ...
(Date:5/21/2013)... study led by George Washington University Professor Tianshu ... ice in small droplets is strongly size-dependent, an ... nanoscale. The formation of ice at the nanoscale ... answer also has important implications for climate research ... ice from supercooled water is generally initiated by ...
(Date:5/21/2013)... Smarter Security, Inc., provider of premium, ... that Genzyme, a Sanofi company and leading biotech company, ... for a multi-use facility in the United States. With ... buildings, this latest order underscores the satisfaction and success ... device improving doorway access control. , “We ...
(Date:5/21/2013)... Md. , May 21, 2013  MacroGenics, ... 1 study of margetuximab (MGAH22), an Fc-modified chimeric ... tumors expressing the HER2 oncoprotein," will be presented ... Society of Clinical Oncology during the Developmental Therapeutics ... 3 at 4:15 – 4:30 PM.  The presentation ...
Breaking Biology Technology:Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 2Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 3Prosonix Initiates Phase 2 Clinical Study with PSX1002 in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) 4Study led by GW professor provides better understanding of water's freezing behavior at nanoscale 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 2Door Security at Genzyme, a Sanofi Company, Enhanced with Door Detective from Smarter Security 3MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
... ... ... ... ...
... ... ... ... ...
... ... ... ... ...
Cached Biology Technology:Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 2Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 3Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 4Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 5Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 6Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 7Nutrastar International, Inc. to Present at the 2010 Rodman & Renshaw Annual China Investment Conference in Beijing 8Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 2Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 3Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 4Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 5Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 6Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 7Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 8Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 9Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 10Sigma-Aldrich(R) Focuses on Biology With Launch of New Life Science Brand Platform 11China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 2China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 3China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 4China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 5China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 6China-Biotics, Inc. Appointed Grayling as Strategic Investor Relations Advisor 7
(Date:5/21/2013)... the nation,s land and water resources could likely support ... 25 billion gallons of algae-based fuel a year in ... , The findings come from an in-depth look at ... significant amounts of algae in large, specially built shallow ... issue of Environmental Science and Technology , published ...
(Date:5/21/2013)... a class of pharmaceuticals can both prevent and treat ... as "TSPO ligands," are currently used for certain types ... TSPO ligand in young adult mice when pathology was ... pathology was quite severe," said lead researcher Christian Pike ... reduced measures of pathology and improved behavior at both ...
(Date:5/21/2013)... all types become most deadly when they metastasize and ... this stage, it becomes very difficult for doctors to ... Now, researchers at the University of Missouri have found ... tumor cells wherever they may be in the body. ... MU College of Veterinary Medicine, says being able to ...
Breaking Biology News(10 mins):Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4Drugs found to both prevent and treat Alzheimer's disease in mice 2MU researchers develop radioactive nanoparticles that target cancer cells 2
... MIT scientists have found a new way that DNA can ... discovering that a mold used to cast a metal tool ... shapes each showing distinct functional roles. Professor Manolis Kellis ... 1 issue of the journal Genes & Development that in ...
... Advanced Public Safety Minimizes ... Cost and Increases Accuracy -, WALL, N.J., ... International, Inc. (OTC Bulletin Board: BKYI), a leader ... Advanced Public Safety (APS), a leading provider of ...
... Cold Spring Harbor Laboratorys (CSHL) researcher Raffaella Sordella, Ph.D. ... Foundation to Conquer Lung Cancer. The two-year grant will ... class of genetic mutations that appear to be a ... of cancer deaths in the United States. The ...
Cached Biology News:MIT reports new twist in microRNA biology 2Missouri Police Department Introduces Electronic Traffic Citations 2Missouri Police Department Introduces Electronic Traffic Citations 3Missouri Police Department Introduces Electronic Traffic Citations 4Cold Spring Harbor Laboratory's lung cancer research program awarded $100,000 grant 2
UBN-1 (C-20)...
Mouse HAI-1 Ectodomain MAb (Clone 199732)...
Human IL-29/IFN-lambda 1 Biotinylated Affinity Purified PAb...
Anti-Potassium Channel EAG-1 Immunogen: Synthetic peptide from the C-terminus of rat Kv10.1 (Accession Q63472). The immunogen sequence is identical in mouse and 14/16 residues identical in human...
Biology Products: